The landscape of EGFR pathways and personalized management of non-small-cell lung cancer

被引：13

作者：

Cheng, Liang ^{[1
]}

Zhang, Shaobo ^{[1
]}

Alexander, Riley ^{[1
]}

Yao, Yongxue ^{[1
]}

MacLennan, Gregory T. ^{[2
]}

Pan, Chong-xian ^{[3
]}

Huang, Jiaoti ^{[4
]}

Wang, Mingsheng ^{[1
]}

Montironi, Rodolfo ^{[5
]}

Lopez-Beltran, Antonio ^{[6
]}

机构：

[1] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

[2] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA

[3] Univ Calif Davis, Dept Internal Med, Div Hematol Oncol, Sacramento, CA 95817 USA

[4] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA

[5] Polytech Univ Marche Reg Ancona, United Hosp, Inst Pathol Anat & Histopathol, Ancona, Italy

[6] Univ Cordoba, Dept Pathol, Cordoba, Spain

来源：

FUTURE ONCOLOGY | 2011年 / 7卷 / 04期

关键词：

EGF receptor; EML4-ALK; FISH; lung cancer; molecular genetic pathology; non-small-cell lung cancer; personalized medicine; targeted therapy; tyrosine kinase inhibitor; EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR EGFR; GENE COPY NUMBER; TYROSINE KINASE INHIBITORS; IN-SITU HYBRIDIZATION; ANAPLASTIC LYMPHOMA KINASE; RESOLUTION MELTING ANALYSIS; PREVIOUSLY TREATED PATIENTS; EML4-ALK FUSION GENE; MULTICENTER PHASE-II;

D O I：

10.2217/FON.11.25

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Two classes of anti-EGF receptor (EGFR) agents, monoclonal anti-EGFR antibodies and small-molecule EGFR tyrosine kinase inhibitors, have been used for the treatment of non-small-cell lung cancer (NSCLC). However, only a subset of patients will benefit from EGFR-targeted therapy. The discovery of biomarkers that select the appropriate patients for the therapy and predict the responses to the therapy is urgently needed. Molecular genetic analyses provide new insights into EGFR pathway alterations and demonstrate promise for predicting the clinical outcome of patients with NSCLC. In this article, we summarize the latest available knowledge on the clinical impact of EGFR mutations, gene copy number, EGFR overexpression, phosphorylation expression and the alteration of the EGFR pathway downstream factors in predicting the response to EGFR-targeted therapy in NSCLC patients. The role of KRAS and BRAF mutations and ALK rearrangement in lung cancer-targeted therapy, are also reviewed.

引用

页码：519 / 541

页数：23

共 184 条

[31] Somatic mutations affect key pathways in lung adenocarcinoma [J].

Ding, Li ;

Getz, Gad ;

Wheeler, David A. ;

Mardis, Elaine R. ;

McLellan, Michael D. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Greulich, Heidi ;

Muzny, Donna M. ;

Morgan, Margaret B. ;

Fulton, Lucinda ;

Fulton, Robert S. ;

Zhang, Qunyuan ;

Wendl, Michael C. ;

Lawrence, Michael S. ;

Larson, David E. ;

Chen, Ken ;

Dooling, David J. ;

Sabo, Aniko ;

Hawes, Alicia C. ;

Shen, Hua ;

Jhangiani, Shalini N. ;

Lewis, Lora R. ;

Hall, Otis ;

Zhu, Yiming ;

Mathew, Tittu ;

Ren, Yanru ;

Yao, Jiqiang ;

Scherer, Steven E. ;

Clerc, Kerstin ;

Metcalf, Ginger A. ;

Ng, Brian ;

Milosavljevic, Aleksandar ;

Gonzalez-Garay, Manuel L. ;

Osborne, John R. ;

Meyer, Rick ;

Shi, Xiaoqi ;

Tang, Yuzhu ;

Koboldt, Daniel C. ;

Lin, Ling ;

Abbott, Rachel ;

Miner, Tracie L. ;

Pohl, Craig ;

Fewell, Ginger ;

Haipek, Carrie ;

Schmidt, Heather ;

Dunford-Shore, Brian H. ;

Kraja, Aldi ;

Crosby, Seth D. ;

Sawyer, Christopher S. .

NATURE, 2008, 455 (7216) :1069-1075

[32] Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial [J].

Douillard, Jean-Yves ;

Shepherd, Frances A. ;

Hirsh, Vera ;

Mok, Tony ;

Socinski, Mark A. ;

Gervais, Radj ;

Liao, Mei-Lin ;

Bischoff, Helge ;

Reck, Martin ;

Sellers, Mark V. ;

Watkins, Claire L. ;

Speake, Georgina ;

Armour, Alison A. ;

Kim, Edward S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) :744-752

[33] Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization -: Why, when, and how? [J].

Dziadziuszko, Rafal ;

Hirsch, Fred R. ;

Varella-Garcia, Marileila ;

Bunn, Paul A., Jr. .

CLINICAL CANCER RESEARCH, 2006, 12 (14) :4409S-4415S

[34] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[35] Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation [J].

Endoh, Hideki ;

Ishibashi, Yasunori ;

Yamaki, Ei ;

Yoshida, Takeshi ;

Yajima, Toshiki ;

Kimura, Hitoshi ;

Kosaka, Takayuki ;

Onozato, Ryoichi ;

Tanaka, Shigebumi ;

Mitsudomi, Tetsuya ;

Kuwano, Hiroyuki .

LUNG CANCER, 2009, 63 (02) :241-246

[36] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

[37] Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor [J].

Ercan, D. ;

Zejnullahu, K. ;

Yonesaka, K. ;

Xiao, Y. ;

Capelletti, M. ;

Rogers, A. ;

Lifshits, E. ;

Brown, A. ;

Lee, C. ;

Christensen, J. G. ;

Kwiatkowski, D. J. ;

Engelman, J. A. ;

Jaenne, P. A. .

ONCOGENE, 2010, 29 (16) :2346-2356

[38] A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. [J].

Felip, Enriclueta ;

Rojo, Federico ;

Reck, Martin ;

Heller, Astrid ;

Klughammer, Barbara ;

Sala, Gemma ;

Cedres, Susana ;

Peralta, Sergio ;

Maacke, Heiko ;

Foernzler, Dorothee ;

Parera, Marta ;

Moecks, Joachim ;

Saura, Cristina ;

Gatzemeier, Ulrich ;

Baselga, Jose .

CLINICAL CANCER RESEARCH, 2008, 14 (12) :3867-3874

[39] Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer [J].

Fukui, Tomoya ;

Ohe, Yuichiro ;

Tsuta, Koji ;

Furuta, Koh ;

Sakamoto, Hiromi ;

Takano, Toshimi ;

Nokihara, Hiroshi ;

Yamamoto, Noboru ;

Sekine, Ikuo ;

Kunitoh, Hideo ;

Asamura, Hisao ;

Tsuchida, Takaaki ;

Kaneko, Masahiro ;

Kusumoto, Masahiko ;

Yamamoto, Seiichiro ;

Yoshida, Teruhiko ;

Tamura, Tomohide .

CLINICAL CANCER RESEARCH, 2008, 14 (15) :4751-4757

[40] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

← 1 2 3 4 5 6 7 8 9 10 →